p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism

Annals of Neurology

Volumn 52, Issue 5, 2002, Pages 597-606

  Duan, Wenzhen ^a   Zhu, Xiaoxiang ^a   Ladenheim, Bruce ^b   Yu, Qian Sheng ^a   Guo, Zhihong ^a   Oyler, Jon ^c   Cutler, Roy G ^a   Cadet, Jean Lud ^b   Greig, Nigel H ^a   Mattson, Mark P ^a,d  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Molecular Neuropsychiatry Section   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYL 2 [4,5,6,7 TETRAHYDRO 2 IMINO 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1 PHENYL 2 [4,5,6,7 TETRAHYDRO 2 IMINO 6 METHYL 3(2H) BENZOTHIAZOLYL]ETHANONE HYDROBROMIDE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 (CYCLOPROPYLMETHYL) 4,5,6,7 TETRAHYDRO 2(3H) BENZOTHIAZOLIMINE HYDROBROMIDE; APOPTOSIS INDUCING FACTOR; DOPAMINE; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN P53; PROTEIN P53 INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; Z 1 113; Z 1 117; Z 1 143;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SYNTHESIS; MALE; MITOCHONDRIAL RESPIRATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; STRIATONIGRAL DEGENERATION; SYMPTOMATOLOGY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; DOPAMINE; DOPAMINE AGENTS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLES; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036829557     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10350     Document Type: Article

References (52)

1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
2. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72-S84.
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
5. Lucking CB, Brice A. Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci 2000;57:1894-1908.
6. Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000;97:13354-13359.
7. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 2000;3:1301-1306.
8. Double KL, Gerlach M, Youdim MB, Riederer P. Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl 2000;60:37-58.
9. Logroscino G, Marder K, Cote L, et al. Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study. Ann Neurol 1996;39:89-94.
10. Yasui K, Kowa H, Nakaso K, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-440.
11. Duan W, Zhang Z, Gash DM, Mattson MP. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann Neurol 1999;46:587-597.
12. Schneider JS, Yuwiler A, Markham CH. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res 1987;411:144-150.
13. Moratalla R, Quinn B, DeLanney LE, et al. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1992;89:3859-3863.
14. Bezard E, Dovero S, Bioulac B, Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 1997;148:288-292.
15. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998;13:S35-S38.
16. Hartley A, Stone JM, Heron C, et al. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: Relevance to Parkinson's disease. J Neurochem 1994;63:1987-1990.
17. Seaton TA, Cooper JM, Schapira AH. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 1997;777:110-118.
18. Mattson MP. Apoptosis and neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1:120-129.
19. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8 hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203.
20. Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 1999;96:5774-5779.
21. Sheikh MS, Fornace AJ Jr. Role of p53 family members in apoptosis. J Cell Physiol 2000;182:171-181.
22. de la Monte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997;152:73-83.
23. Blum D, Wu Y, Nissou MF, et al. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res 1997;751:139-142.
24. Crumrine RC, Thomas AL, Morgan PF. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J Cereb Blood Flow Metab 1994;14:887-891.
25. Napieralski JA, Raghupathi R, McIntosh TK. The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury. Mol Brain Res 1999;71:78-86.
26. Cregan SP, MacLaurin JG, Craig CG, et al. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 1999;19:7860-7869.
27. Sakhi S, Bruce A, Sun N, et al. Induction of rumor suppressor p53 and DNA fragmentation in organotypic hippocampal cultures following excitotoxin treatment. Exp Neurol 1997;145:81-88.
28. Morrison RS, Wenzel HJ, Kinoshita Y, et al. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J Neurosci 1996;16:1337-1345.
29. Trimmer PA, Smith TS, Jung AB, Bennett JP Jr. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996;5:233-239.
30. Hirata H, Cadet JL. p53 knockout mice are protected against the long term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 1997;69:780-790.
31. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-1737.
32. Culmsee C, Zhu X, Yu QS, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001;77:220-228.
33. Zhu X, Yu QS, Cutler RG, et al. Design and synthesis of novel p53 inhibitors as neuroprotective agents. J Med Chem (in press).
34. Duan W, Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 1999;57:195-206.
35. Zaczek R, Coyle JT. Rapid and simple method for measuring biogenic amine and metabolites in brain homogenates by HPLC with electrochemical detection. J Neural Transm 1982;53:1-5.
36. Ladenheim B, Krasnova IN, Deng X, et al. Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 2000;58:1247-1256.
37. Guo Q, Fu W, Xie J, et al. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med 1998;4:957-962.
38. Morris EJ, Keramaris E, Rideout HJ, et al. Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage. J Neurosci 2001;21:5017-5026.
39. Mogi M, Togari A, Kondo T, et al. Caspase activities and tumor necrosis factor receptor RI (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 2000;107:335-341.
40. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
41. Turmel H, Hartmann A, Parain K, et al. Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov Disord 2001;16:185-119.
42. Viswanath V, Wu Y, Boonplueang R, et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 2001;21:9519-9528.
43. Vila M, Jackson-Lewis V, Vukosavic S, et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:2837-2842.
44. Eberhardt O, Coelln RV, Kugler S, et al. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2000;20:9126-9134.
45. Mochizuki H, Hayakawa H, Migita M, et al. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 2001;98:10918-10923.
46. Greig NH. Drug entry to the brain and its pharmacological manipulation. In: Bradbury MWB, ed. Handbook of Experimental Pharmacology. Vol 103. Heidelberg: Springer-Verlag, 1992:487-523.
47. Taylor CA, Saint-Hilaire MH, Cupples LA, et al. Environmental, medical, and family history risk factors for Parkinson's disease: A New England based case control study. Am J Med Genet 1999;88:742-749.
48. Soldner F, Weller M, Haid S, et al. MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). Exp Cell Res 1999;250:75-85.
49. Saha AR, Ninkina NN, Hange DP, et al. Induction of neuronal death by alpha-synuclein. Eur J Neurosci 2000;12:3073-3077.
50. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001;10:919-926.
51. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-1815.
52. Attardi LD, Jacks T. The role of p53 in tumour suppression: Lessons from mouse models. Cell Mol Life Sci 1999;55:48-63.